相似文献
1
Replacement of a thiourea-S with an amidine-NH donor group in a platinum-acridine antitumor compound reduces the metal's reactivity with cysteine sulfur.
J Med Chem. 2009 May 28;52(10):3424-7. doi: 10.1021/jm900451y.
2
Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair.
Mol Pharm. 2011 Oct 3;8(5):1941-54. doi: 10.1021/mp200309x. Epub 2011 Aug 17.
3
Thermally inert metal ammines as light-inducible DNA-targeted agents. Synthesis, photochemistry, and photobiology of a prototypical rhodium(III)-intercalator conjugate.
Inorg Chem. 2002 Dec 30;41(26):7159-69. doi: 10.1021/ic025744n.
4
Effect of linkage geometry on biological activity in thiourea- and guanidine-substituted acridines and platinum-acridines.
Bioorg Med Chem Lett. 2008 Jul 1;18(13):3799-801. doi: 10.1016/j.bmcl.2008.05.043. Epub 2008 May 16.
5
Design, synthesis, and biological activity of a novel non-cisplatin-type platinum-acridine pharmacophore.
J Med Chem. 2001 Dec 6;44(25):4492-6. doi: 10.1021/jm010293m.
6
Synthesis and biological evaluation of platinum-acridine hybrid agents modified with bipyridine non-leaving groups.
Bioorg Med Chem Lett. 2009 Jul 1;19(13):3423-5. doi: 10.1016/j.bmcl.2009.05.046. Epub 2009 May 18.
7
PT-ACRAMTU, a platinum-acridine anticancer agent, lengthens and aggregates, but does not stiffen or soften DNA.
Cell Biochem Biophys. 2013;67(3):1103-13. doi: 10.1007/s12013-013-9614-8.
8
Cysteine-Directed Bioconjugation of a Platinum(II)-Acridine Anticancer Agent.
Inorg Chem. 2019 Jan 7;58(1):43-46. doi: 10.1021/acs.inorgchem.8b02717. Epub 2018 Dec 13.
9
Bis(acridinylthiourea)platinum(II) complexes: synthesis, DNA affinity, and biological activity in glioblastoma cells.
Bioorg Med Chem Lett. 2003 Mar 10;13(5):855-8. doi: 10.1016/s0960-894x(02)01078-8.
10
DNA-binding antitumor agents: from pyrimido[5,6,1-de]acridines to other intriguing classes of acridine derivatives.
Curr Med Chem. 2002 Sep;9(18):1701-16. doi: 10.2174/0929867023369268.
引用本文的文献
1
Development of Prodrug-Payloads for Targeted Therapeutic Applications of Platinum-Acridine Anticancer Agents.
Bioconjug Chem. 2023 Oct 18;34(10):1873-1881. doi: 10.1021/acs.bioconjchem.3c00368. Epub 2023 Oct 9.
2
Recent Progress in Cyclic Aryliodonium Chemistry: Syntheses and Applications.
Chem Rev. 2023 Jan 17;123(4):1364-416. doi: 10.1021/acs.chemrev.2c00591.
3
Development of Novel Pt-Labeled Hoechst33258: Pt Is More Suitable than In for Targeting DNA.
J Med Chem. 2022 Apr 14;65(7):5690-5700. doi: 10.1021/acs.jmedchem.1c02209. Epub 2022 Mar 31.
4
DNA Adduct Detection after Post-Labeling Technique with PCR Amplification (DNA-ADAPT-qPCR) Identifies the Pre-ribosomal RNA Gene as a Direct Target of Platinum-Acridine Anticancer Agents.
Chemistry. 2021 Oct 21;27(59):14681-14689. doi: 10.1002/chem.202102263. Epub 2021 Sep 23.
5
Discovery of a Chiral DNA-Targeted Platinum-Acridine Agent with Potent Enantioselective Anticancer Activity.
Angew Chem Int Ed Engl. 2020 Dec 1;59(49):21965-21970. doi: 10.1002/anie.202009983. Epub 2020 Sep 29.
6
Cysteine-Directed Bioconjugation of a Platinum(II)-Acridine Anticancer Agent.
Inorg Chem. 2019 Jan 7;58(1):43-46. doi: 10.1021/acs.inorgchem.8b02717. Epub 2018 Dec 13.
7
Platination of cysteine by an epidermal growth factor receptor kinase-targeted hybrid agent.
Chem Commun (Camb). 2018 Jul 11;54(54):7479-7482. doi: 10.1039/c8cc04251a. Epub 2018 Jun 19.
8
Design and cellular studies of a carbon nanotube-based delivery system for a hybrid platinum-acridine anticancer agent.
J Inorg Biochem. 2016 Dec;165:170-180. doi: 10.1016/j.jinorgbio.2016.07.016. Epub 2016 Jul 27.
9
Design of enzymatically cleavable prodrugs of a potent platinum-containing anticancer agent.
Chemistry. 2014 Dec 1;20(49):16164-73. doi: 10.1002/chem.201404675. Epub 2014 Oct 10.
10
Mechanism of the palladium-catalyzed hydrothiolation of alkynes to thioethers: a DFT study.
J Mol Model. 2014 Sep;20(9):2409. doi: 10.1007/s00894-014-2409-z. Epub 2014 Aug 20.
本文引用的文献
1
A non-cross-linking platinum-acridine agent with potent activity in non-small-cell lung cancer.
J Med Chem. 2008 Dec 11;51(23):7574-80. doi: 10.1021/jm800900g.
2
Tuning the DNA conformational perturbations induced by cytotoxic platinum-acridine bisintercalators: effect of metal cis/trans isomerism and DNA threading groups.
J Med Chem. 2008 Jun 12;51(11):3069-72. doi: 10.1021/jm8003569. Epub 2008 May 6.
3
Cisplatin nephrotoxicity: a review.
Am J Med Sci. 2007 Aug;334(2):115-24. doi: 10.1097/MAJ.0b013e31812dfe1e.
4
The resurgence of platinum-based cancer chemotherapy.
Nat Rev Cancer. 2007 Aug;7(8):573-84. doi: 10.1038/nrc2167. Epub 2007 Jul 12.
5
Effect of the diamine nonleaving group in platinum-acridinylthiourea conjugates on DNA damage and cytotoxicity.
J Med Chem. 2007 May 3;50(9):2259-63. doi: 10.1021/jm0614376. Epub 2007 Apr 5.
6
Adenine-N3 in the DNA minor groove - an emerging target for platinum containing anticancer pharmacophores.
Anticancer Agents Med Chem. 2007 Jan;7(1):125-38. doi: 10.2174/187152007779313991.
7
The role of sulfur in platinum anticancer chemotherapy.
Anticancer Agents Med Chem. 2007 Jan;7(1):19-34. doi: 10.2174/187152007779314062.
8
Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry.
Chem Res Toxicol. 2006 May;19(5):622-6. doi: 10.1021/tx060058c.
9
Guanine binding of a cytotoxic platinum-acridin-9-ylthiourea conjugate monitored by 1-D 1H and 2-D [1H,15N] NMR spectroscopy: hydrolysis is not the rate-determining step.
J Inorg Biochem. 2006 May;100(5-6):972-9. doi: 10.1016/j.jinorgbio.2005.12.021. Epub 2006 Feb 20.
10
Characterization of the bisintercalative DNA binding mode of a bifunctional platinum-acridine agent.
Nucleic Acids Res. 2005 Sep 28;33(17):5622-32. doi: 10.1093/nar/gki869. Print 2005.
Zotero 插件